secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001140361-25-037060
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance
---------------------------------------------------------------------------

- Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.
- Med Tech segment $35.3M (+26.1%): Auryon +20.1%, thrombectomy +41.2%, NanoKnife +26.7%.
- Adjusted EBITDA $2.2M vs ($0.2M) prior year; cash $38.8M, debt-free.
- Raised FY2026 guidance: net sales $308-$313M, adj EBITDA $6-$10M, adj EPS ($0.33)-($0.23).
- Enrolled first patients in AMBITION BTK and RECOVER-AV trials; PRESERVE study published.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036125037060/0001140361-25-037060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036125037060/ef20056554_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-037060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer